|
Market Cap (19-May) $4,758,880 (1,313th) |
Close (30-Jun) $1.51 |
Volume (30-Jun) 12,937 |
Shortsold (8-Aug) 2,108 (0.02%) (508th) |
|
52w High $1.09 |
52w Low $0.280 |
P/E - |
EPS -0.42 |
ZLD released this announcement to the ASX on 31 May 2023, 11:46. The announcement is not marked as price sensitive, and is 9 page(s) in length and 1.88MB in size.
You can view all announcements from ZLD and see how they appear on a price chart on the announcements page.
At the date of this announcement, ZLD was 0.031% short sold according to ASIC data. It was ranked the 485th most shorted stock on the ASX. It remains ranked 508th as of the latest reported data (08 August 2024).
| Other Recent Announcements from ZLD | |
|---|---|
| Amendment to ASX announcement - Zelira's diabetic nerve pai | 8 June 2023, 9:47 |
| Initial Director's Interest Notice | 1 June 2023, 15:29 |
| Final Director's Interest Notice | 1 June 2023, 15:27 |
| Top Line Results Investor Presentation | 31 May 2023, 11:46 |
| Investor Webinar - Top line trial results | 31 May 2023, 10:41 |
| Zeliras diabetic nerve pain drug outperforms Lyrica | 31 May 2023, 10:22 |
| Trading Halt | 29 May 2023, 9:06 |
You must be logged in to post a reply.
Zelira Therapeutics 